Published in Drug Week, October 17th, 2003
The technology is covered by a pending NIH patent application, detailing the use of heat energy to activate and control gene therapy and the construction of various heat-sensitive "Gene Therapy Constructs." Under the license agreement, Celsion has the exclusive rights to develop heat-sensitive gene therapy products activated by microwave heat energy.
Celsion believes that its proprietary microwave-focused heating technology, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.